Krystal Biotech, Inc. $KRYS Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 8.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 520,925 shares of the company’s stock after selling 49,228 shares during the quarter. William Blair Investment Management LLC owned approximately 1.76% of Krystal Biotech worth $173,239,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP boosted its position in Krystal Biotech by 28.6% during the 3rd quarter. Allworth Financial LP now owns 603 shares of the company’s stock worth $201,000 after acquiring an additional 134 shares during the last quarter. Fifth Third Bancorp raised its holdings in shares of Krystal Biotech by 1.4% in the third quarter. Fifth Third Bancorp now owns 6,611 shares of the company’s stock valued at $2,199,000 after purchasing an additional 90 shares during the last quarter. New Mexico Educational Retirement Board acquired a new stake in shares of Krystal Biotech in the third quarter valued at approximately $1,829,000. Jacobi Capital Management LLC acquired a new stake in shares of Krystal Biotech in the third quarter valued at approximately $56,000. Finally, New York Life Investment Management LLC lifted its position in shares of Krystal Biotech by 10.4% in the third quarter. New York Life Investment Management LLC now owns 3,497 shares of the company’s stock worth $1,163,000 after purchasing an additional 330 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on KRYS shares. The Goldman Sachs Group assumed coverage on shares of Krystal Biotech in a report on Thursday, September 24th. They set a “buy” rating and a $441.00 target price for the company. Citigroup decreased their target price on shares of Krystal Biotech from $416.00 to $412.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Royal Bank Of Canada lowered their price target on shares of Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 3rd. TD Cowen cut their price target on shares of Krystal Biotech from $403.00 to $380.00 and set a “buy” rating on the stock in a research report on Tuesday, November 3rd. Finally, HC Wainwright restated a “buy” rating and set a $361.00 price objective on shares of Krystal Biotech in a research note on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $375.00.

Get Our Latest Research Report on KRYS

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $305.23 on Monday. The company has a market capitalization of $9.04 billion, a P/E ratio of 41.42 and a beta of 0.56. Krystal Biotech, Inc. has a 12 month low of $198.02 and a 12 month high of $382.54. The stock has a 50 day moving average of $326.76 and a 200-day moving average of $309.70.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The business had revenue of $127.34 million for the quarter, compared to analysts’ expectations of $125.77 million. Analysts predict that Krystal Biotech, Inc. will post 7.74 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

(Free Report)

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.

Further Reading

Institutional Ownership by Quarter for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.